The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Discontinuation
Page 4 of 4 of this archive, newest first.
Every fortnight, every third week, seasonally: an unstudied practice
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
What happens when the drug is taken away: three randomised answers
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Why people actually stop, in the order they actually stop
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.
What SURMOUNT-1 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
What happens when the drug is taken away: three randomised answers
The regain trajectories, arm by arm, with the estimands named.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Seasonal use, holiday use, and the honest state of the evidence
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
A design note on withdrawal trials, and why the run-in matters
A withdrawal trial answers a narrower question than it appears to. This piece states which question.